|
rs121913530
|
|
|
0.730 |
GeneticVariation |
BEFREE |
<i>KRAS p.G12C</i>, which occurs in approximately 14% of lung adenocarcinomas, 3-5% of colorectal cancers, and low levels in other solid tumors, represents an attractive therapeutic target for covalent inhibitors.
|
31531201 |
2019 |
|
rs121913530
|
|
A |
0.730 |
GeneticVariation |
CLINVAR |
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
|
25044103 |
2014 |
|
rs121913530
|
|
A |
0.730 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913530
|
|
|
0.730 |
GeneticVariation |
BEFREE |
KRAS-G12C mutation is associated with worse DFS and OS in resected lung AC.
|
25170638 |
2014 |
|
rs121913530
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Presence of the KRAS G12C mutation had 96% specificity and positive predictive value for lung adenocarcinoma, whereas G12R was 99% specific for pancreatic cancer with a positive predictive value of 86%.
|
23887294 |
2014 |
|
rs17851045
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
|
31410985 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Kras<sup>LSL-G12D/WT</sup>, Kras<sup>LSL-G12D/WT</sup>; Lkb1<sup>Flox/Flox</sup> and Kras<sup>LSL-G12D/WT</sup>; p53<sup>Flox/Flox</sup> mouse models of lung adenocarcinoma, we monitored an impaired progression of tumors upon RANKL blockade.
|
29223537 |
2018 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we have investigated the delivery and transfection of wild-type (wt-) p53 and microRNA-125b (miR-125b) expressing plasmid DNA, in SK-LU-1 human lung adenocarcinoma cells as well as in Kras(G12D)/p53(fl/fl) (KP) genetically engineered mouse model of lung cancer.
|
26686386 |
2016 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Semi-supervised clustering, based on KRAS(G12D) mutant expression and a risk score representing expression of 69 lung adenocarcinoma-prognostic genes, classified PDX cells into four groups.
|
26084335 |
2015 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
|
26372703 |
2015 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, these profiles did not segregate by histology (lung adenocarcinoma-appendiceal cancer (KRAS G12D and GNAS R201C), and lung adenocarcinoma-liposarcoma (CDK4 and MDM2 amplification pairs)).
|
26418953 |
2015 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Indeed, lung tissue-specific inactivation of Stat3 in mice results in increased Kras(G12D)-driven AC initiation and malignant progression leading to markedly reduced survival.
|
25734337 |
2015 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood.
|
24213573 |
2014 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development.
|
21471965 |
2011 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the attempt to find alternative therapeutic regimes for such patients, we tested PHA-848125, an oral pan cyclin-dependent kinase inhibitor currently under evaluation in phase II clinical trial, on a transgenic mouse model, K-Ras(G12D)LA2, which develops pulmonary cancerous lesions reminiscent of human lung adenocarcinomas.
|
20197397 |
2010 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To examine how the MYC and K-ras(G12D) oncogenes cooperate for the initiation and maintenance of tumorigenesis, we generated double conditional transgenic tumor models of lung adenocarcinoma and lymphoma.
|
18461184 |
2008 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Limd1(-/-) mice are predisposed to chemical-induced lung adenocarcinoma and genetic inactivation of Limd1 in mice heterozygous for oncogenic K-Ras(G12D) markedly increased tumor initiation, promotion, and mortality.
|
19060205 |
2008 |